Evaluation of Asymmetric Dimethylarginine (ADMA) Levels in Children with Growth Hormone Deficiency
Evaluation of Asymmetric Dimethylarginine (ADMA) Levels in Children with Growth Hormone Deficiency
复制标题
DOI：
10.4274/jcrpe.1182
复制
发表时间：
2014-01-01
影响因子：
1.9
通讯作者：
Bas, Veysel Nijat
中科院分区：
文献类型：
--
作者：
Onder, Asan;Aycan, Zehra;Bas, Veysel Nijat
目的：调查单纯性生长激素缺乏症（GHD）儿童血清不对称二甲基精氨酸（ADMA）水平，并确定GH替代疗法对这些水平的影响。方法：纳入31例诊断为单纯性GHD的患者和29名年龄和性别匹配的健康儿童。测量了所有受试者的身高、体重和腰围。评估空腹血清胰岛素样生长因子-1 (IGF-1)、IGF结合蛋白-3、葡萄糖、胰岛素和脂质水平。使用酶联免疫吸附测定技术评估血清 ADMA 水平。对 28 例 GHD 病例在治疗第 3 个月和第 6 个月重复进行相同的评估。结果：患者组和对照组之间的 ADMA 水平没有显着差异 [0.513 +/- 0.130 (0.291-0.820) mu mol/L vs. 0.573 +/- 0.199 (0.241-1.049) mu mol/L]。对照组血清ADMA与HbA1c水平呈正相关。在 GHD 病例中，ADMA 水平与高密度脂蛋白水平呈负相关，与低密度脂蛋白水平呈正相关。与治疗前水平相比，接受 GH 治疗的患者 ADMA 水平也显着升高 [血清 ADMA 水平，治疗第 3 个月为 1.075 +/- 0.133 (0.796-1.303) mu mol/L，治疗第 6 个月为 0.923 +/- 0.121 (0.695-1.159) mu mol/L]。第 6 个月评估时，ADMA 水平与胰岛素抵抗值的稳态模型评估之间呈负相关。在治疗前或治疗期间，ADMA 水平与年龄、性别或青春期状态之间没有关系。结论：发现 GHD 患者和健康儿童的血清 ADMA 水平相似。然而，GH 替代治疗后 GHD 患者的血清 ADMA 水平显着升高。
Objective: To investigate serum asymmetric dimethylarginine (ADMA) levels in children with isolated growth hormone deficiency (GHD) and to determine the effect of GH replacement therapy on these levels.Methods: 31 patients diagnosed with isolated GHD and 29 age-and sex-matched healthy children were enrolled in the study. Height, weight and waist circumference were measured in all subjects. Fasting serum insulin-like growth factor-1 (IGF-1), IGF binding protein-3, glucose, insulin and lipid levels were evaluated. Serum ADMA levels were assessed using the enzyme-linked immunosorbent assay technique. The same evaluations were repeated on the 3rd and 6th months of treatment in 28 of the GHD cases.Results: There were no significant differences in ADMA levels between the patient and control groups [0.513 +/- 0.130 (0.291-0.820) mu mol/L vs. 0.573 +/- 0.199 (0.241-1.049) mu mol/L]. There was a positive correlation between serum ADMA and HbA1c levels in the control group. In the GHD cases, ADMA levels negatively correlated with high-density lipoprotein levels and positively correlated with low-density lipoprotein levels. There was also a significant increase in ADMA levels in patients receiving GH therapy compared to pre-treatment levels [serum ADMA level, 1.075 +/- 0.133 (0.796-1.303) mu mol/L at the 3rd month and 0.923 +/- 0.121 (0.695-1.159) mu mol/L at the 6th month of treatment]. There was a negative correlation between ADMA levels and homeostasis model assessment of insulin resistance values at the 6th month evaluation. There were no relationships between ADMA levels and age, sex, or pubertal state either before or during the treatment.Conclusion: Serum ADMA levels were found to be similar in patients with GHD and in healthy children. However, serum ADMA levels showed a significant increase in GHD patients following GH replacement therapy.